{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:41:05Z","timestamp":1791222065912,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02363570"],"award-info":[{"award-number":["GR-2016-02363570"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02363570"],"award-info":[{"award-number":["GR-2016-02363570"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02363570"],"award-info":[{"award-number":["GR-2016-02363570"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and purpose<\/jats:title>\n            <jats:p>Shwachman-Diamond Syndrome (SDS) is an autosomal recessive disease belonging to the inherited bone marrow failure syndromes and characterized by hypocellular bone marrow, exocrine pancreatic insufficiency, and skeletal abnormalities. SDS is associated with increased risk of developing myelodysplastic syndrome (MDS) and\/or acute myeloid leukemia (AML). Although SDS is not primarily considered an inflammatory disorder, some of the associated conditions (e.g., neutropenia, pancreatitis and bone marrow dysfunction) may involve inflammation or immune system dysfunctions. We have already demonstrated that signal transducer and activator of transcription (STAT)-3 and mammalian target of rapamycin (mTOR) were hyperactivated and associated with elevated IL-6 levels in SDS leukocytes. In this study, we analyzed the level of phosphoproteins involved in STAT3 and mTOR pathways in SDS lymphoblastoid cells (LCLs) and the secretomic profile of soluble pro-inflammatory mediators in SDS plasma and LCLs in order to investigate the systemic inflammation in these patients and relative pathways.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Twenty-six SDS patients and seven healthy donors of comparable age were recruited during the programmed follow-up visits for clinical evaluation at the Verona Cystic Fibrosis Center Human. The obtained samples (plasma and\/or LCLs) were analyzed for: phosphoproteins, cytokines, chemokines and growth factors levels by Bio-plex technology; microRNAs profiling by next generation sequencing (NGS) and microRNAs expression validation by\u00a0Real Time-PCR (RT-PCR) and droplet digital PCR (ddPCR) .<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We demonstrated dysregulation of ERK1\/2 and AKT phosphoproteins in SDS, as their involvement in the hyperactivation of the STAT3 and mTOR pathways confirmed the interplay of these pathways in SDS pathophysiology. However, both these signaling pathways are strongly influenced by the inflammatory environment. Here, we reported that SDS is characterized by elevated plasma levels of several soluble proinflammatory mediators. In vitro experiments show that these pro-inflammatory genes are closely correlated with STAT3\/mTOR pathway activation. In addition, we found that miR-181a-3p is down-regulated in SDS. Since this miRNA acts as a regulator of several pro-inflammatory pathways such as STAT3 and ERK1\/2, its down-regulation may be a driver of the constitutive inflammation observed in SDS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The results obtained in this study shed light on the complex pathogenetic mechanism underlying bone marrow failure and leukemogenesis in SDS, suggesting the need for anti-inflammatory therapies for SDS patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10020-025-01133-5","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:21:08Z","timestamp":1740723668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Constitutive systemic inflammation in Shwachman-Diamond Syndrome"],"prefix":"10.1186","volume":"31","author":[{"given":"Giuseppe","family":"Sabbioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"D\u2019Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Breveglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Finotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gambari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Bezzerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Borgatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"1","key":"1133_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1042\/BST20110609","volume":"40","author":"E Aksamitiene","year":"2012","unstructured":"Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras\/MAPK and survival PI3K\/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40(1):139\u201346. https:\/\/doi.org\/10.1042\/BST20110609.","journal-title":"Biochem Soc Trans"},{"key":"1133_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","volume":"60","author":"C Alfaro","year":"2017","unstructured":"Alfaro C, Sanmamed MF, Rodr\u00edguez-Ruiz ME, Teijeira \u00c1, O\u00f1ate C, et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev. 2017;60:24\u201331. https:\/\/doi.org\/10.1016\/j.ctrv.2017.08.004.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1133_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41375-021-01480-2","volume":"36","author":"JLJC Assmann","year":"2022","unstructured":"Assmann JLJC, Leon LG, Stavast CJ, van den Bogaerdt SE, Schilperoord-Vermeulen J, et al. miR-181a is a novel player in the STAT3-mediated survival network of TCR\u03b1\u03b2+ CD8+ T large granular lymphocyte leukemia. Leukemia. 2022;36(4):983\u201393. https:\/\/doi.org\/10.1038\/s41375-021-01480-2.","journal-title":"Leukemia"},{"issue":"1","key":"1133_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0014-5793(92)80909-z","volume":"307","author":"M Baggiolini","year":"1992","unstructured":"Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307(1):97\u2013101. https:\/\/doi.org\/10.1016\/0014-5793(92)80909-z.","journal-title":"FEBS Lett"},{"issue":"5","key":"1133_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","volume":"26","author":"Z Bakouny","year":"2020","unstructured":"Bakouny Z, Choueiri TK. IL-8 and cancer prognosis on immunotherapy. Nat Med. 2020;26(5):650\u20131. https:\/\/doi.org\/10.1038\/s41591-020-0873-9.","journal-title":"Nat Med"},{"key":"1133_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.blre.2019.04.004","volume":"36","author":"T Banerjee","year":"2019","unstructured":"Banerjee T, Calvi LM, Becker MW, Liesveld JL. Flaming and fanning: the spectrum of inflammatory influences in myelodysplastic syndromes. Blood Rev. 2019;36:57\u201369. https:\/\/doi.org\/10.1016\/j.blre.2019.04.004.","journal-title":"Blood Rev"},{"issue":"2","key":"1133_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40291-018-0368-2","volume":"23","author":"V Bezzerri","year":"2019","unstructured":"Bezzerri V, Cipolli M. Shwachman-Diamond syndrome: molecular mechanisms and current perspectives. Mol Diagn Ther. 2019;23(2):281\u201390. https:\/\/doi.org\/10.1007\/s40291-018-0368-2.","journal-title":"Mol Diagn Ther"},{"key":"1133_CR8","doi-asserted-by":"publisher","first-page":"33165","DOI":"10.1038\/srep33165","volume":"6","author":"V Bezzerri","year":"2016","unstructured":"Bezzerri V, Vella A, Calcaterra E, Finotti A, Gasparello J, et al. New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes. Sci Rep. 2016;6:33165. https:\/\/doi.org\/10.1038\/srep33165.","journal-title":"Sci Rep"},{"issue":"6","key":"1133_CR9","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.3892\/ol.2018.8587","volume":"15","author":"C Bian","year":"2018","unstructured":"Bian C, Liu Z, Li D, Zhen L. PI3K\/AKT inhibition induces compensatory activation of the MET\/STAT3 pathway in non-small cell lung cancer. Oncol Lett. 2018;15(6):9655\u201362. https:\/\/doi.org\/10.3892\/ol.2018.8587.","journal-title":"Oncol Lett"},{"issue":"1","key":"1133_CR10","doi-asserted-by":"publisher","first-page":"7186","DOI":"10.1038\/s41467-022-34965-4","volume":"13","author":"H Bolouri","year":"2022","unstructured":"Bolouri H, Ries RE, Wiedeman AE, Hylkema T, Scheiding S, et al. Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes. Nat Commun. 2022;13(1):7186. https:\/\/doi.org\/10.1038\/s41467-022-34965-4.","journal-title":"Nat Commun"},{"issue":"1","key":"1133_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/cancers10010023","volume":"10","author":"F Conciatori","year":"2018","unstructured":"Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, et al. mTOR Cross-talk in cancer and potential for combination therapy. Cancers (Basel). 2018;10(1):23. https:\/\/doi.org\/10.3390\/cancers10010023.","journal-title":"Cancers (Basel)."},{"issue":"17","key":"1133_CR12","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/onc.2014.164","volume":"34","author":"KM Dodd","year":"2015","unstructured":"Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2015;34(17):2239\u201350. https:\/\/doi.org\/10.1038\/onc.2014.164.","journal-title":"Oncogene"},{"issue":"9","key":"1133_CR13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3324\/haematol.2011.057489","volume":"97","author":"J Donadieu","year":"2012","unstructured":"Donadieu J, Fenneteau O, Beaupain B, Beaufils S, Bellanger F, et al. Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. Haematologica. 2012;97(9):1312\u20139. https:\/\/doi.org\/10.3324\/haematol.2011.057489.","journal-title":"Haematologica"},{"issue":"3","key":"1133_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1365-2141.2001.02996.x","volume":"114","author":"Y Dror","year":"2001","unstructured":"Dror Y, Ginzberg H, Dalal I, Cherepanov V, Downey G, et al. Immune function in patients with Shwachman-Diamond syndrome. Br J Haematol. 2001;114(3):712\u20137. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02996.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"1133_CR15","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood-2003-01-0114","volume":"102","author":"C Dufour","year":"2003","unstructured":"Dufour C, Corcione C, Svahn J, Haupt R, Poggi V, Nandor B\u00e9kassy AN, Scime R, Pistorio A, Pistoia V. TNF-\u03b1 and IFN-\u03b3 are overexpressed in the bone marrow of Fanconi anemia patients and TNF-\u03b1 suppresses erythropoiesis in vitro. Blood. 2003;102(6):2053\u20139. https:\/\/doi.org\/10.1182\/blood-2003-01-0114.","journal-title":"Blood"},{"issue":"4","key":"1133_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.5858\/2002-126-0452-PPOIBM","volume":"126","author":"MT Elghetany","year":"2002","unstructured":"Elghetany MT, Alter BP. p53 protein overexpression in bone marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia. Arch Pathol Lab Med. 2002;126(4):452\u20135. https:\/\/doi.org\/10.5858\/2002-126-0452-PPOIBM.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"1133_CR17","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/ajmg.a.61593","volume":"182","author":"E Furutani","year":"2020","unstructured":"Furutani E, Shah AS, Zhao Y, Andorsky D, Dedeoglu F, et al. Inflammatory manifestations in patients with Shwachman-Diamond syndrome: a novel phenotype. Am J Med Genet A. 2020;182(7):1754\u201360. https:\/\/doi.org\/10.1002\/ajmg.a.61593.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"1133_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1182\/bloodadvances.2021005539","volume":"6","author":"E Furutani","year":"2022","unstructured":"Furutani E, Liu S, Galvin A, Steltz S, Malsch MM, et al. Hematologic complications with age in Shwachman-Diamond syndrome. Blood Adv. 2022;6(1):297\u2013306. https:\/\/doi.org\/10.1182\/bloodadvances.2021005539.","journal-title":"Blood Adv"},{"issue":"S1","key":"1133_CR19","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2019-128607","volume":"134","author":"J Gasparello","year":"2019","unstructured":"Gasparello J, Papi C, Breveglieri G, D\u2019Aversa A, Bezzerri V, et al. A signature of differentially expressed Micrornas in lymphoblastoid cells from Shwachman-Diamond syndrome patients indicates possible molecular targets for mirna therapeutics. Blood. 2019;134(S1):2504. https:\/\/doi.org\/10.1182\/blood-2019-128607.","journal-title":"Blood"},{"issue":"5","key":"1133_CR20","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.3892\/or.2014.3440","volume":"32","author":"I Gkouveris","year":"2014","unstructured":"Gkouveris I, Nikitakis N, Karanikou M, Rassidakis G, Sklavounou A. Erk1\/2 activation and modulation of STAT3 signaling in oral cancer. Oncol Rep. 2014;32(5):2175\u201382. https:\/\/doi.org\/10.3892\/or.2014.3440.","journal-title":"Oncol Rep"},{"issue":"1","key":"1133_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1189\/jlb.0709499","volume":"88","author":"AD Gregory","year":"2010","unstructured":"Gregory AD, Capoccia BJ, Woloszynek JR, Link DC. Systemic levels of G-CSF and interleukin-6 determine the angiogenic potential of bone marrow resident monocytes. J Leukoc Biol. 2010;88(1):123\u201331. https:\/\/doi.org\/10.1189\/jlb.0709499.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"1133_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/j.seminhematol.2022.01","volume":"59","author":"EM Groarke","year":"2022","unstructured":"Groarke EM, Calado RT, Liu JM. Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: Overlapping pathophysiology with therapeutic implications. Semin Hematol. 2022;59(1):30\u20137. https:\/\/doi.org\/10.1053\/j.seminhematol.2022.01.","journal-title":"Semin Hematol"},{"issue":"8","key":"1133_CR23","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ptr.5109","volume":"28","author":"A Guerrini","year":"2014","unstructured":"Guerrini A, Mancini I, Maietti S, Rossi D, Poli F, et al. Expression of pro-inflammatory interleukin-8 is reduced by ayurvedic decoctions. Phytother Res. 2014;28(8):1173\u201381. https:\/\/doi.org\/10.1002\/ptr.5109.","journal-title":"Phytother Res"},{"issue":"6","key":"1133_CR24","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","volume":"184","author":"H Hammad","year":"2002","unstructured":"Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2002;184(6):1469\u201385. https:\/\/doi.org\/10.1016\/j.cell.2021.02.016.","journal-title":"Cell"},{"issue":"1","key":"1133_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12887-023-04324-3","volume":"23","author":"X Han","year":"2023","unstructured":"Han X, Lu S, Gu C, Bian Z, Xie X, et al. Clinical features, epidemiology, and treatment of Shwachman-Diamond syndrome: a systematic review. BMC Pediatr. 2023;23(1):503. https:\/\/doi.org\/10.1186\/s12887-023-04324-3.","journal-title":"BMC Pediatr"},{"issue":"2","key":"1133_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/iid3.292","volume":"8","author":"MB Hansen","year":"2020","unstructured":"Hansen MB. Interleukin-6 signaling requires only few IL-6 molecules: relation to physiological concentrations of extracellular IL-6. Immun Inflamm Dis. 2020;8(2):170\u201380. https:\/\/doi.org\/10.1002\/iid3.292.","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"1133_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/s41418-021-00764-5","volume":"28","author":"A Helbling-Leclerc","year":"2021","unstructured":"Helbling-Leclerc A, Garcin C, Rosselli F. Beyond DNA repair and chromosome instability-Fanconi anaemia as a cellular senescence-associated syndrome. Cell Death Differ. 2021;28(4):1159\u201373. https:\/\/doi.org\/10.1038\/s41418-021-00764-5.","journal-title":"Cell Death Differ"},{"issue":"6092","key":"1133_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324(6092):73\u20136. https:\/\/doi.org\/10.1038\/324073a0.","journal-title":"Nature"},{"issue":"2","key":"1133_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clbc.2015.11.006","volume":"16","author":"K Jhaveri","year":"2016","unstructured":"Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, et al. Hyperactivated mTOR and JAK2\/STAT3 Pathways: molecular drivers and potential therapeutic targets of inflammatory and invasive ductal breast cancers after neoadjuvant chemotherapy. Clin Breast Cancer. 2016;16(2):113-22.e1. https:\/\/doi.org\/10.1016\/j.clbc.2015.11.006.","journal-title":"Clin Breast Cancer"},{"issue":"24","key":"1133_CR30","doi-asserted-by":"publisher","first-page":"9652","DOI":"10.3390\/ijms21249652","volume":"21","author":"K Kapralova","year":"2020","unstructured":"Kapralova K, Jahoda O, Koralkova P, Gursky J, Lanikova L, Pospisilova D, Divoky V, Horvathova M. Oxidative DNA damage, inflammatory signature, and altered erythrocytes properties in diamond-blackfan anemia. Int J Mol Sci. 2020;21(24):9652. https:\/\/doi.org\/10.3390\/ijms21249652.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1133_CR31","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3324\/haematol.2023.282949","volume":"108","author":"N Kawashima","year":"2023","unstructured":"Kawashima N, Oyarbide U, Cipolli M, Bezzerri V, Corey SJ. Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants. Haematologica. 2023a;108(10):2594\u2013605. https:\/\/doi.org\/10.3324\/haematol.2023.282949.","journal-title":"Haematologica"},{"issue":"8","key":"1133_CR32","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/biom13081249","volume":"13","author":"N Kawashima","year":"2023","unstructured":"Kawashima N, Bezzerri V, Corey SJ. The molecular and genetic mechanisms of inherited bone marrow failure syndromes: the role of inflammatory cytokines in their pathogenesis. Biomolecules. 2023b;13(8):1249. https:\/\/doi.org\/10.3390\/biom13081249.","journal-title":"Biomolecules"},{"key":"1133_CR33","doi-asserted-by":"publisher","first-page":"18411","DOI":"10.1038\/srep18411","volume":"5","author":"A Kuett","year":"2015","unstructured":"Kuett A, Rieger C, Perathoner D, Herold T, Wagner M, et al. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci Rep. 2015;5:18411. https:\/\/doi.org\/10.1038\/srep18411.","journal-title":"Sci Rep"},{"key":"1133_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.imbio.2005.05.001","volume":"210","author":"R Lang","year":"2005","unstructured":"Lang R. Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology. 2005;210:63\u201376. https:\/\/doi.org\/10.1016\/j.imbio.2005.05.001.","journal-title":"Immunobiology"},{"key":"1133_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.exphem.2017.08.003","volume":"55","author":"AJ Li","year":"2017","unstructured":"Li AJ, Calvi LM. The microenvironment in myelodysplastic syndromes: Niche- mediated disease initiation and progression. Exp Hematol. 2017;55:3\u201318. https:\/\/doi.org\/10.1016\/j.exphem.2017.08.003.","journal-title":"Exp Hematol"},{"issue":"4","key":"1133_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21(4):183\u2013203. https:\/\/doi.org\/10.1038\/s41580-019-0199-y.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"17","key":"1133_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152673","volume":"132","author":"Y Mei","year":"2022","unstructured":"Mei Y, Ren K, Liu Y, Ma A, Xia Z, Han X, Li E, Tariq H, Bao H, Xie X, Zou C, Zhang D, Li Z, Dong L, Verma A, Lu X, Abaza Y, Altman JK, Sukhanova M, Yang J, Ji P. Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia. J Clin Invest. 2022;132(17): e152673. https:\/\/doi.org\/10.1172\/JCI152673.","journal-title":"J Clin Invest"},{"issue":"6","key":"1133_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320\u20138. https:\/\/doi.org\/10.1016\/j.tibs.2011.03.006.","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"1133_CR39","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.12490","volume":"95","author":"A Mercuri","year":"2015","unstructured":"Mercuri A, Cannata E, Perbellini O, Cugno C, Balter R, Zaccaron A, et al. Immunophenotypic analysis of hematopoiesis in patients suffering from Shwachman-Bodian-Diamond Syndrome. Eur J Haematol. 2015;95(4):308\u201315. https:\/\/doi.org\/10.1111\/ejh.12490.","journal-title":"Eur J Haematol"},{"issue":"2","key":"1133_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161\u201370. https:\/\/doi.org\/10.1056\/NEJMra1202117.","journal-title":"N Engl J Med"},{"issue":"1","key":"1133_CR41","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2020.012","volume":"12","author":"P Qiang","year":"2020","unstructured":"Qiang P, Pan Q, Fang C, Fozza C, Song K, et al. MicroRNA-181a-3p as a diagnostic and prognostic biomarker for acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2020;12(1): e2020012. https:\/\/doi.org\/10.4084\/MJHID.2020.012.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"1133_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ijc.2910450216","volume":"45","author":"S Roncella","year":"1990","unstructured":"Roncella S, Ramarli D, Cooper MK, Forni M, Caretto P, et al. Establishment of an EBV-positive lymphoblastoid cell line that grows as a lymphoma in nude mice and expresses membrane CD2 molecules. Int J Cancer. 1990;45(2):299\u2013307. https:\/\/doi.org\/10.1002\/ijc.2910450216.","journal-title":"Int J Cancer"},{"issue":"12","key":"1133_CR43","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1182\/blood-2005-11-4370","volume":"107","author":"PS Rosenberg","year":"2006","unstructured":"Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107(12):4628\u201335.","journal-title":"Blood"},{"issue":"2","key":"1133_CR44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood-2005-11-4370","volume":"150","author":"PS Rosenberg","year":"2010","unstructured":"Rosenberg PS, Zeidler C, Bolyard AA, Bonilla MA, Boxer LA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010;150(2):196\u20139. https:\/\/doi.org\/10.1182\/blood-2005-11-4370.","journal-title":"Br J Haematol"},{"issue":"10","key":"1133_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.18632\/aging.100824","volume":"7","author":"E Roth","year":"2015","unstructured":"Roth E, Cao J. MiR-181 suppresses metastasis via MMP-14. Aging. 2015;7(10):740\u20131. https:\/\/doi.org\/10.18632\/aging.100824.","journal-title":"Aging"},{"issue":"3","key":"1133_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","volume":"61","author":"B Sanchez-Correa","year":"2013","unstructured":"Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Ba\u00f1as H, Morgado S, Casado JG, Solana R, Tarazona R. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61(3):885\u201391. https:\/\/doi.org\/10.1016\/j.cyto.2012.12.023.","journal-title":"Cytokine"},{"issue":"36","key":"1133_CR47","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1200\/JCO.2010.29.2953","volume":"28","author":"S Schwind","year":"2010","unstructured":"Schwind S, Maharry K, Radmacher MD, Mr\u00f3zek K, Holland KB, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(36):5257\u201364. https:\/\/doi.org\/10.1200\/JCO.2010.29.2953.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1133_CR48","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/jcp.2010.077677","volume":"63","author":"N Shah","year":"2010","unstructured":"Shah N, Cambrook H, Koglmeier J, Mason C, Ancliff P, et al. Enteropathic histopathological features may be associated with Shwachman-Diamond syndrome. J Clin Pathol. 2010;63(7):592\u20134. https:\/\/doi.org\/10.1136\/jcp.2010.077677.","journal-title":"J Clin Pathol"},{"key":"1133_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.canlet.2018.04.010","volume":"427","author":"CJ Stavast","year":"2018","unstructured":"Stavast CJ, Leenen PJM, Erkeland SJ. The interplay between critical transcription factors and microRNAs in the control of normal and malignant myelopoiesis. Cancer Lett. 2018;427:28\u201337. https:\/\/doi.org\/10.1016\/j.canlet.2018.04.010.","journal-title":"Cancer Lett"},{"issue":"5","key":"1133_CR50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41419-019-1599-9","volume":"10","author":"Y Su","year":"2019","unstructured":"Su Y, Yuan J, Zhang F, Lei Q, Zhang T, et al. MicroRNA-181a-5p and microRNA-181a-3p cooperatively restrict vascular inflammation and atherosclerosis. Cell Death Dis. 2019;10(5):365. https:\/\/doi.org\/10.1038\/s41419-019-1599-9.","journal-title":"Cell Death Dis"},{"issue":"9","key":"1133_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nsmb.2879","volume":"21","author":"DC Swarts","year":"2014","unstructured":"Swarts DC, Makarova K, Wang Y, Nakanishi K, Ketting RF, et al. The evolutionary journey of Argonaute proteins. Nat Struct Mol Biol. 2014;21(9):743\u201353. https:\/\/doi.org\/10.1038\/nsmb.2879.","journal-title":"Nat Struct Mol Biol"},{"key":"1133_CR52","doi-asserted-by":"publisher","first-page":"1603990","DOI":"10.3389\/phrs.2021.1603990","volume":"42","author":"P Tavakoli","year":"2021","unstructured":"Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, Grimm MC. A review of inflammatory bowel disease: a model of microbial, immune and neuropsychological integration. Public Health Rev. 2021;42:1603990. https:\/\/doi.org\/10.3389\/phrs.2021.1603990.","journal-title":"Public Health Rev"},{"issue":"6","key":"1133_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005288","volume":"11","author":"ME Tourlakis","year":"2015","unstructured":"Tourlakis ME, Zhang S, Ball HL, Gandhi R, Liu H, et al. In vivo senescence in the sbds-deficient murine pancreas: cell-type specific consequences of translation insufficiency. PLoS Genet. 2015;11(6): e1005288. https:\/\/doi.org\/10.1371\/journal.pgen.1005288.","journal-title":"PLoS Genet"},{"issue":"3","key":"1133_CR54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/cancers12030597","volume":"12","author":"A Vella","year":"2020","unstructured":"Vella A, D\u2019Aversa E, Api M, Breveglieri G, Allegri M, et al. mTOR and STAT3 pathway hyper-activation is associated with elevated interleukin-6 levels in patients with Shwachman-Diamond syndrome: further evidence of lymphoid lineage impairment. Cancers (Basel). 2020;12(3):597. https:\/\/doi.org\/10.3390\/cancers12030597.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"1133_CR55","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/febs.13285","volume":"282","author":"MS Wake","year":"2015","unstructured":"Wake MS, Watson CJ. STAT3 the oncogene - still eluding therapy? FEBS J. 2015;282(14):2600\u201311. https:\/\/doi.org\/10.1111\/febs.13285.","journal-title":"FEBS J"},{"issue":"4","key":"1133_CR56","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3892\/ijo.2014.2259","volume":"44","author":"SW Wang","year":"2014","unstructured":"Wang SW, Sun YM. The IL-6\/JAK\/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 2014;44(4):1032\u201340. https:\/\/doi.org\/10.3892\/ijo.2014.2259.","journal-title":"Int J Oncol"},{"issue":"5","key":"1133_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cancergen.2014.12.006","volume":"208","author":"H Weng","year":"2015","unstructured":"Weng H, Lal K, Yang FF, Chen J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 2015;208(5):225\u20139. https:\/\/doi.org\/10.1016\/j.cancergen.2014.12.006.","journal-title":"Cancer Genet"},{"key":"1133_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s0960-9822(99)00268-7","volume":"10","author":"K Yokogami","year":"2000","unstructured":"Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of stat3 during CNTF signaling is mediated by the rapamycin target mTOR Curr. Biol. 2000;10:47\u201350. https:\/\/doi.org\/10.1016\/s0960-9822(99)00268-7.","journal-title":"Biol"},{"key":"1133_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.ctdb.2016.01.009","volume":"118","author":"VW Yu","year":"2016","unstructured":"Yu VW, Scadden DT. Hematopoietic Stem Cell and Its Bone Marrow Niche. Curr Top Dev Biol. 2016;118:21\u201344. https:\/\/doi.org\/10.1016\/bs.ctdb.2016.01.009.","journal-title":"Curr Top Dev Biol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01133-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:21:12Z","timestamp":1740723672000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01133-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01133-5","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Azienda Ospedaliera Universitaria Integrata (Verona, Italy: approval No. 4182 CESC). Informed consent was obtained from participants or their legal representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agree to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}